Overview
Javascript is curently disabled in your browser. Several features of this site wil not function whilst javascript is disabled.open aces to scientific and medical researchPapers PublishedOpen aces per-reviewed scientific and medical journals.Learn moreDove Medical Pres is a member of the OAI.Learn moreBulk reprints for the pharmaceutical industry.Learn moreWe ofer real benefits to our authors, including fast-track procesing of papers.Learn moreRegister your specific details and specific drugs of interest and we wil match the information you provide to articles from our extensive database and email PDF copies to you promptly.Learn moreBack to Journals » International Journal of Nephrology and Renovascular Disease » Volume 15 Authors Nashar K, Khalil P Received 23 May 202 Acepted for publication 12 October 202 Published 1 November 202 Volume 202:15 Pages 289—308 DOI htps:/doi.org/10.2147/IJNRD.S234282 Checked for plagiarism Yes Review by Single anonymous per review Per reviewer coments 3 Editor who aproved publication: Profesor Pravin Singhal Khaled Nashar, Patricia Khalil Department of Medicine, Alegheny Health Network, Pitsburgh, PA, USACorespondence: Khaled Nashar; Patricia Khalil, Email [email protected]; [email protected]Abstract: Dapagliflozin is a selective sodium–glucose cotransporter 2 (SGLT2) inhibitor that was recently aproved in the USA and the EU for the treatment of adults with chronic kidney disease (CKD) with or without diabetes melitus (DM).
Details
The DAPA-CKD trial showed a 39% decline in the risk of worsening kidney function, onset of end-stage kidney disease, or kidney failure-related death. Patients with lower levels of eGFR and higher levels of albuminuria are among those who stand to gain the greatest absolute benefits. These benefits were similar in both patients with or without diabetes, thus underming the hypothesis that these drugs mitigate glycemia-related nephrotoxicity.